Previous studies have reported a 1% BC risk and a 3% pancreatic cancer risk for men carrying PALB2 variants by age 80 (Tedaldi et al. 2020), underlying its relevant role in MBC predisposition and the importance of developing a surveillance protocol for male carriers. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.